附件 99.1
Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
MALVERN, PA., November 12, 2024 – Neuronetics, Inc. (NASDAQ: STIM) (the 「Company」 or 「Neuronetics」) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2024.
第三季度2024亮點
| • | Third quarter 2024 revenue of $18.5 million, a 4% increase as compared to the third quarter 2023 |
| • | U.S. NeuroStar Advanced Therapy system revenue of $4.1該季度的金額爲48台系統 |
| • | 2023年第三季度，美國治療會話收入增加了2% |
最近的運營和營銷亮點
| • | neuronetics 股東批准了對的收購 Greenbrook TMS公司，成爲該國領先的精神衛生護理提供商之一 TMS在11月 8, 2024 |
| • | AACAP 2024年度會議上的NeuroStar口頭展示突出了對抑鬱症青少年TMS療效進行評估的最大研究 |
| • | 已有超過188,000名全球患者接受了6.9萬次治療百萬次治療 會話 |
「我們對收購Greenbrook TMS的批准感到非常興奮，這讓neuronetics成爲美國最大、最具創新性的心理健康護理提供者之一，」 neuronetics的總裁兼首席執行官Keith J. Sullivan說。「這一戰略性整合將顯著增強我們通過一個統一的商業機構擴大心理健康解決方案的能力，同時也爲加快推出額外服務如SPRAVATO創造機會，」® 在我們的網絡中。通過利用我們的互補優勢，包括Greenbrook在美國的廣泛存在和neuronetics領先行業的技術和培訓計劃——我們正在打造一個具有獨特能力的組織，以增加患者獲取、改善結果，最終爲股東創造價值。”
Keith J. Sullivan繼續說：「除了Greenbrook收購，我們在第三季度的戰略舉措中取得了持續進展，其中包括我們青少年治療項目的強勁勢頭，以及我們針對性營銷努力的令人鼓舞的早期結果。我們對自己能夠爲患者、提供者和股東創造有意義的價值並推動心理健康治療的能力比以往任何時候都更有信心。」
2024年第三季度截至2024年9月30日的財務和運營結果
| 按地理位置劃分的營收 截至9月30日的三個月。 |
||||||||||||
| 2024 | 2023 | |||||||||||
| 金額 | 金額 | % 變化 | ||||||||||
| (未經審計；以千爲單位，除百分比外) | ||||||||||||
| 美國交易法案交易所 |
$ | 17,922 | $ | 17,211 | 4 | % | ||||||
| 國際 |
608 | 673 | (10 | )% | ||||||||
|
|
|
|
|
|
|
|||||||
| 總收入 |
$ | 18,530 | $ | 17,884 | 4 | % | ||||||
|
|
|
|
|
|
|
|||||||
2024年9月30日結束的三個月總收入爲1850萬美元，比2023年第三季度的1790萬美元增長了4%。在本季度，美國總收入增長了4%，國際收入與2023年第三季度相比略有下降。美國收入增長主要歸因於美國治療課程和美國NeuroStar Advanced Therapy系統的銷售持續增加。
| 按產品類別劃分的美國收入 截至9月30日的三個月 |
||||||||||||
| 2024 | 2023 | |||||||||||
| 金額 | 金額 | % 變動 | ||||||||||
| （未經審計；以千計，除百分比外） | ||||||||||||
| NeuroStar Advanced Therapy系統 |
$ | 4,108 | $ | 3,597 | 14 | % | ||||||
| 治療會話 |
13,326 | $ | 13,060 | 2 | % | |||||||
| 其他 |
488 | $ | 554 | (12 | )% | |||||||
|
|
|
|
|
|
|
|||||||
| 美國總收入 |
$ | 17,922 | $ | 17,211 | 4 | % | ||||||
|
|
|
|
|
|
|
|||||||
2024年9月30日結束的三個月內，U.S. neuronetics Advanced Therapy System的收入爲410萬美元，比2023年第三季度的360萬美元增長14%。 2024年9月30日和2023年的三個月內，公司分別發貨了49臺和43台系統。
2024年9月30日結束的三個月內，美國治療會話收入爲1330萬美元，比2023年第三季度的1310萬美元增長2%。
2024年第三季度，每個活躍站點的美國治療會話收入爲11390美元，而2023年第三季度爲11917美元。
2024年第三季度的毛利率爲75.6%，比2023年第三季度的65.8%提高了約980個點子。 毛利率的增加是由於產品組合的變化，以及缺少 一次性的 2023年發生的由我方新合同製造商承擔的製造成本及庫存減值。
2024年第三季度營業費用爲2170萬美元，比2023年第三季度的2060萬美元增加110萬美元，增幅爲5%。
2024年第三季度淨損失爲1330萬美元，每股虧損044美元，與2023年第三季度淨損失940萬美元，每股虧損033美元相比。每股淨損失基於2024年第三季度和2023年第三季度分別爲30,267,236股和28,875,720股的加權平均普通股份。
2024年第三季度EBITDA爲1160萬美元，與2023年第三季度EBITDA的770萬美元相比。請參閱附表，調和了EBITDA，這是一種財務衡量方法，與淨損失。 非美國通用會計準則（non-GAAP） 財務衡量上的淨損失可轉換爲現金和現金等價物。
截至2024年9月30日，現金及現金等價物爲2090萬美元。相比之下，截至2023年12月31日，現金及現金等價物爲5970萬美元。
股東批准收購Greenbrook TMS
On November 8, 2024, Neuronetics’ stockholders approved the previously announced acquisition of Greenbrook TMS Inc. (「Greenbrook」), in which Neuronetics will acquire all of the outstanding common shares of Greenbrook in an 全股票 transaction. The next step in finalizing the transaction is a hearing in respect of the Final Order pursuant to the Ontario Business Corporations Act scheduled for November 15, 2024. The transaction will create a vertically integrated organization capable of providing access to mental health treatment with significant scale in the U.S. The transaction offers multiple strategic benefits for Neuronetics and its customers, including increased brand awareness for NeuroStar, more consistent delivery of best practices, and the ability to offer a variety of positive benefits for all NeuroStar customers. Beyond the strategic benefits, the transaction is expected to create compelling financial benefits, including increased revenue scale and a strong growth trajectory, material cost synergies, an accelerated path to profitability, and a bolstered balance sheet.
The Company has outlined several key strategic initiatives, including merging Neuronetics’ sales team with Greenbrook’s regional area managers to optimize commercial operations, implementing the Better Me Provider Program best practices across all Greenbrook sites, and accelerating the rollout of SPRAVATO® treatment across the combined network. Through these initiatives and additional identified opportunities to optimize the combined company’s cost structure in connection with the transaction, the Company now expects to achieve cash flow breakeven by the second quarter of 2025.
NeuroStar TMS Data Presented at Leading Child & Adolescent Psychiatry Conference Shows Strong Efficacy in Treating Teen Depression
At the 2024 American Academy of Child and Adolescent Psychiatry (「AACAP」) annual meeting, Neuronetics presented data from the largest study to date evaluating transcranial magnetic stimulation (「TMS」) in adolescents with major depressive disorder. In an oral presentation, Paul E. Croarkin, DO, MS of Mayo Clinic shared compelling results showing NeuroStar’s strong efficacy in treating Major Depressive Disorder (「MDD」) in adolescent patients, with impressive response and remission rates of 78% and 48% respectively. The findings were similar to those previously reported in adult populations treated with NeuroStar TMS including clinically meaningful improvement in anxiety symptoms in this MDD population. As the only FDA批准的 抑鬱症的一線輔助治療TMS設備 適用於年齡在 15-21, 這些發現進一步證實了NeuroStar在爲青少年精神健康治療提供創新解決方案方面的領導地位。
業務前景
2024年第四季度，獨立運營的公司預計全球總收入在1900萬美元到2000萬美元之間。
2024年全年，獨立運營的公司預計全球總收入爲7100萬美元到7200萬美元之間。
2024年全年，獨立運營的公司預計總營業費用爲8100萬美元到8200萬美元之間。該預測不包括 閉市前 交易成本約爲$2.0百萬美元。
網絡直播和電話會議信息 NeuroPace將在2024年5月8日週三美國東部時間下午4:30舉行電話會議，討論2024年第一季度的財務業績。有興趣聽會議的投資者，可以通過訪問會議現場的實時和存檔網絡直播來參加該會議。對於希望通過電話參加電話會議的人，可以撥打+1-888-886-7786並引用會議ID 48339803進行通話。網絡直播將存檔在公司的投資者關係網站上，可供活動後至少90天的重播。
Neuronetics管理團隊將於2024年11月12日上午8:30舉辦電話會議，時間爲美國東部時間。
電話會議將通過網絡直播，僅限聽取模式。 https://edge.media-server.com/mmc/p/yk5bidgv. 要在電話上收聽會議，請註冊參加通話。 here雖然不是必須的，但建議您在活動開始前10分鐘加入。
關於Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a 無藥物 noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration (the 「FDA」) for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety information and indications for use, visit NeuroStar.com.
「安全港」聲明：1995年《私人證券訴訟改革法案》下的「安全港」聲明：
Statements in the press release regarding the Company that are not historical facts constitute 「forward-looking statements」 within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as 「outlook,」 「potential,」 「believe,」 「expect,」 「plan,」 「anticipate,」 「predict,」 「may,」 「will,」 「could,」 「would」 and 「should」 as well as the negative of these terms and similar expressions. These statements include those relating to the Company’s business outlook and current expectations for upcoming quarters and fiscal year 2024, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the Arrangement with Greenbrook, initially announced on August 11, 2024 and approved by Greenbrook’s shareholders and Neuronetics stockholders on November 8, 2024, on our business relationships, operating results and business generally; the Company’s ability to execute its business strategy; the Company’s ability to achieve or sustain profitable operations due to its history of losses; the Company’s reliance on the sale and use of its NeuroStar Advanced Therapy system to generate revenues; the scale and efficacy of the Company’s salesforce; the Company’s ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using the Company’s products; physician and patient demand for treatments using the Company’s products; developments in competing technologies and therapies for the indications that the Company’s products treat; product defects; our revenue has been concentrated among a small number of customers; the Company’s ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy system for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; the terms of our credit facility; our ability to successfully 推出 我們關注Better Me Provider計劃的計劃時間表；我們的自我可持續性和現有的現金餘額；以及我們能夠在2025年第三季度實現現金流盈虧平衡。有關這些和其他相關風險的討論，請參閱公司最近在美國證券交易委員會（「SEC」）的備案文件，在SEC網站www.sec.gov上可以找到。這些前瞻性聲明基於公司對本新聞稿日期的期望和假設。除非法律要求，否則公司將不承擔更新本新聞稿中包含的任何前瞻性聲明的責任或義務，這可能是由於新信息、未來事件或公司預期的變化而導致的。
投資者聯繫：
邁克·瓦利或馬克·克勞澤
ICR Healthcare
443-213-0499
ir@neuronetics.com
媒體聯繫人：
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
NEURONETICS, INC.
損益表
(未經審計；單位：千美元，每股數據除外)
| 三個月結束 9月30日， |
截至九個月結束 9月30日, |
|||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| 收入 |
$ | 18,530 | $ | 17,884 | $ | 52,397 | $ | 51,034 | ||||||||
| 營業成本 |
4,529 | 6,120 | 13,129 | 15,100 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| 毛利潤 |
14,001 | 11,764 | 39,268 | 35,934 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| 營業費用： |
||||||||||||||||
| 銷售和市場營銷 |
11,877 | 12,141 | 35,820 | 35,602 | ||||||||||||
| 總務和行政 |
7,436 | 6,339 | 19,540 | 19,151 | ||||||||||||
| 研發 |
2,416 | 2,155 | 6,999 | 7,308 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| 總營業費用 |
21,729 | 20,635 | 62,359 | 62,061 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| 營運虧損 |
(7,728 | ) | (8,871 | ) | (23,091 | ) | (26,127 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| 其他收入/費用： |
||||||||||||||||
| 利息支出 |
1,725 | 1,184 | 5,529 | 3,580 | ||||||||||||
| 償債損失 |
4,427 | — | 4,427 | — | ||||||||||||
| 其他收入，淨額 |
(539 | ) | (664 | ) | (2,001 | ) | (4,895 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| 淨虧損 |
$ | (13,341 | ) | $ | (9,391 | ) | $ | (31,046 | ) | $ | (24,812 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| 每股普通股淨損失，基本和稀釋 |
$ | (0.44 | ) | $ | (0.33 | ) | $ | (1.04 | ) | $ | (0.87 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| 普通股基本和稀釋平均股數 |
30,267 | 28,876 | 29,931 | 28,505 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
NEURONETICS，INC.
資產負債表
(未經審計；以千爲單位，除每股數據外)
| 九月三十日， 2024 |
12月31日， 2023 |
|||||||
| 資產 |
||||||||
| 流動資產： |
||||||||
| 現金及現金等價物 |
$ | 20,867 | $ | 59,677 | ||||
| 應收賬款淨額 |
16,825 | 15,782 | ||||||
| 存貨 |
4,960 | 8,093 | ||||||
| 淨投資於銷售型租賃的流動部分。 |
572 | 905 | ||||||
| 預付佣金費用的流動部分 |
2,921 | 2,514 | ||||||
| 應收票據的流動部分 |
2,477 | 2,056 | ||||||
| 預付款項及其他流動資產 |
4,837 | 4,766 | ||||||
|
|
|
|
|
|||||
| 總流動資產 |
53,459 | 93,793 | ||||||
|
|
|
|
|
|||||
| 資產和設備，淨值 |
1,639 | 2,009 | ||||||
| 經營租賃 租賃權資產 |
2,328 | 2,773 | ||||||
| 以銷售類型租賃爲基礎的淨投資 |
140 | 661 | ||||||
| 預付佣金支出 |
8,733 | 8,370 | ||||||
| 長期應收票據 |
2,878 | 3,795 | ||||||
| 其他 |
4,940 | 4,430 | ||||||
|
|
|
|
|
|||||
| 總資產 |
$ | 74,117 | $ | 115,831 | ||||
|
|
|
|
|
|||||
| 負債和股東權益 |
||||||||
| 流動負債: |
||||||||
| 應付賬款 |
$ | 3,295 | $ | 4,752 | ||||
| 預提費用 |
11,429 | 12,595 | ||||||
| 遞延收入 |
1,311 | 1,620 | ||||||
| 經營租賃負債流動部分 |
862 | 845 | ||||||
|
|
|
|
|
|||||
| 流動負債合計 |
16,897 | 19,812 | ||||||
|
|
|
|
|
|||||
| 長期負債淨額 |
46,002 | 59,283 | ||||||
| 已確認的營業收入 |
4 | 200 | ||||||
| 經營租賃負債 |
1,833 | 2,346 | ||||||
|
|
|
|
|
|||||
| 負債合計 |
64,736 | 81,641 | ||||||
|
|
|
|
|
|||||
| 承諾和 contingencies（注18） |
— | — | ||||||
| 股東權益: |
||||||||
| 優先股，每股面值0.01美元：授權10,000股；截至2024年9月30日和2023年12月31日，均未發行或流通股 |
— | — | ||||||
| 普通股，每股面值0.01美元：授權200,000股；截至2024年9月30日和2023年12月31日，分別發行和流通股爲30,317股和29,092股 |
303 | 291 | ||||||
| 共計實收資本資本金 |
416,205 | 409,980 | ||||||
| 累積赤字 |
(407,127 | ) | (376,081 | ) | ||||
|
|
|
|
|
|||||
| 未經審計的中期簡明合併利潤表 截至2024年6月30日和2023年6月30日的六個月期間 （以美元千元爲單位，每股數據和每股數據除外） |
9,381 | 34,190 | ||||||
|
|
|
|
|
|||||
| 負債合計和股東權益 |
$ | 74,117 | $ | 115,831 | ||||
|
|
|
|
|
|||||
NEURONETICS, INC.
現金流量表
(未經審計；以千計)
| 截至9月30日的9個月 | ||||||||
| 2024 | 2023 | |||||||
| 經營活動產生的現金流量： |
||||||||
| 淨虧損 |
$ | (31,046 | ) | $ | (24,812 | ) | ||
| 調整爲淨損失到經營活動現金流量淨使用： |
||||||||
| 折舊及攤銷 |
1,627 | 1,503 | ||||||
| 信貸損失準備金 |
1,947 | 369 | ||||||
| 存貨減值 |
346 | 1,905 | ||||||
| 股份報酬 |
4,320 | 5,693 | ||||||
| 非現金 利息費用 |
580 | 460 | ||||||
| 償債損失 |
4,427 | — | ||||||
| 某些資產和負債的變動： |
||||||||
| 應收賬款淨額 |
(3,834 | ) | (7,933 | ) | ||||
| 存貨 |
2,718 | (2,742 | ) | |||||
| 收益型租賃淨投資 |
854 | 1,092 | ||||||
| 預付佣金支出 |
(770 | ) | (804 | ) | ||||
| 預付款項和其他資產 |
(374 | ) | (3,338 | ) | ||||
| 應付賬款 |
(1,524 | ) | 54 | |||||
| 應計費用 |
(1,166 | ) | (4,801 | ) | ||||
| 遞延收入 |
(506 | ) | (817 | ) | ||||
|
|
|
|
|
|||||
| 營業活動中使用的淨現金 |
(22,401 | ) | (34,171 | ) | ||||
|
|
|
|
|
|||||
| 投資活動產生的現金流量： |
||||||||
| 購置房地產和設備以及資本化軟件 |
(1,377 | ) | (1,490 | ) | ||||
| 償還應收票據 |
1,340 | 731 | ||||||
|
|
|
|
|
|||||
| 投資活動中使用的淨現金 |
(37 | ) | (759 | ) | ||||
|
|
|
|
|
|||||
| 籌資活動產生的現金流量： |
||||||||
| 債務發行成本支付 |
(2,188 | ) | (863 | ) | ||||
| 長期債務發行所得 |
48,084 | 2,500 | ||||||
| 發行認股權的收入 |
1,916 | — | ||||||
| 償還長期債務 |
(60,000 | ) | (1,200 | ) | ||||
| 償還債務熄滅成本 |
(4,185 | ) | — | |||||
| 行使期權所得款項 |
1 | — | ||||||
|
|
|
|
|
|||||
| 籌資活動中使用的淨現金/提供的淨現金 |
(16,372 | ) | 437 | |||||
|
|
|
|
|
|||||
| 現金及現金等價物淨減少 |
(38,810 | ) | (34,493 | ) | ||||
| 期初的現金及現金等價物 |
59,677 | 70,340 | ||||||
|
|
|
|
|
|||||
| 期末的現金及現金等價物 |
$ | 20,867 | $ | 35,847 | ||||
|
|
|
|
|
|||||
非通用會計準則 財務措施（未經審計）
EBITDA不是美國一般公認會計原則（GAAP）下的財務績效指標，不應被視爲GAAP淨損失的替代或優越。然而，管理層同時使用GAAP和 非美國通用會計準則（non-GAAP） 內部使用金融指標評估和管理公司運營，以更好地了解其業務。此外，管理層認爲，增加 非通用會計準則 財務指標爲投資者提供了有意義的補充信息，並便於分析，以評估公司的財務表現、運營結果和趨勢。公司對EBITDA的計算可能與其他企業報告的相應指標不可比擬，因爲企業和投資者可能在認爲
何種類型的事件需要調整上存在差異。下表將報告的淨虧損調節爲EBITDA：
| 三個月結束 9月30日， |
截至九個月結束 9月30日, |
|||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| （以千爲單位） | (以千爲單位) | |||||||||||||||
| 淨虧損 |
$ | (13,341 | ) | $ | (9,391 | ) | $ | (31,046 | ) | $ | (24,812 | ) | ||||
| 利息支出，淨額 |
1,186 | 1,184 | 3,528 | 3,580 | ||||||||||||
| 所得稅 |
— | — | — | — | ||||||||||||
| 折舊及攤銷 |
512 | 500 | 1,627 | 1,503 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| EBITDA |
$ | (11,643 | ) | $ | (7,707 | ) | $ | (25,891 | ) | $ | (19,729 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||